Cyclic amides of 1,4-diaminobut-2-yne

ABSTRACT

The compounds are 1,4-diaminobut-2-yne derivatives of pyrrolidinone which are useful as central nervous system depressants.

Ilnited States Patent [191 Preed et al.

[ Dec. 24, I974 CYCLIC AMIDES OF 1,4-DIAMINOBUT-2-YNE [75] Inventors: Meier E. Freed, Philadelphia, Pa.;

John L. Archibald, Windsor, England [73] Assignee: American Home Products Corporation, New York, N.Y.

[22] Filed: Sept. 18, 1972 [21] Appl. No.: 291,692

Related US. Application Data [63] Continuation of Ser. No. 1,021, Jan. 6, 1970,

abandoned, which is a continuation-in-part of Ser. No. 599,408, Dec. 16, 1966, abandoned.

[52] US. CL. 260/247.2 A, 260/268 H, 260/293.7l, 260/293.76, 260/293.86, 260/3265 SM, 260/3265 FL, 424/267, 424/274, 424/248 [51] lint. Cl C07d 87/42 58 Field 0rsearciiI36O/2171'2 A, 293713265 FL OTHER PUBLICATIONS Chemical Abstracts, Vol. 63: 5500C, 1965. Chemical Abstracts, Vol. 50: l6786e, 1955.

.Primary Examiner-Lorraine A. Weinberger Assistant Examiner' Paul J. Killos Attorney, Agent, or Firm-Andrew Kafl o [57] ABSTRACT The compounds are 1,4-diaminobut-2-yne derivatives of pyrrolidinone which are useful as central nervous system depressants.

4 Claims, No Drawings CYCLIC AMIDES OF 1,4-DIAMINOBUT-2-YNE This is a continuation of application SerJNo. 1,021, filed Jan. 6, 1970, now abandoned which isa continuation-in-part of application Ser. No. 599,408 filed Dec. 16, i966 and since abandoned.

This invention relates to chemical compounds that are derivatives of l,4-diaminobut-2-yne and, more particularly, to certain cyclic amides thereof, and to methods for preparing the latter.

The compounds of the invention may be represented by the general formula:

wherein n is an integer from 2 to 3; R is of the group consisting of hydrogen, lower alkyl and phenyl; R and R when separate, are each of the group consisting of cological activity. Thus, the compounds of this invention have been found to be useful for their pharmacological activity as central nervous system depressants.

The compounds of this invention may be obtained in a variety of ways, as will appear to those skilled in the art. A most convenient method of preparation has been found by us to be a comparatively simple two-step se' quence. Therein. a suitable imide and propargyl chloride are first reacted in the presence of sodium amide and liquid ammonia to obtain the desired l-propargyl- 2-imide as starting material. The latter is then reacted with a selected aldehyde and a suitable di-substituted amine to obtain the desired compounds of the invention. As indicated in formula I, above, the two substituents on the amine reactant may be joined to form a heterocyclic ring.

The two-step described above is represented schematically in Equations 1 and 2 below:

Many of the reactants employed in the processes of this invention are known compounds which are readily available from commercial sources. Others which are not commercially available can readily be prepared in accordance with standard organic procedures which are known to those skilled in the art.

When the compounds of the invention are employed as central nervous system depressants, they may be administered alone or in combination with pharmaceutically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form oftablets or capsules containing such excipients as starch, milk, sugar, certain types of clay and so forth. They may be administered orally in the form of solutions which may contain coloring and flavoring agents or they may be injected parenterally, that is intramuscularly, intravenously or subcutaneously. For parenteral administration they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.

The dosage of the present therapeutic agents will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular subject under treatment. It will generally be found that when the dosage is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally. In general, the compounds of this invention are most desirably administered at a concentration level that will generally afford effective results without causing any harmful or deleterious side effects and preferably at a level that is in the range of from about 0.02 mg. to about 1.5 mg. per kg. of body weight per day, although as aforementioned variations will occur. However, a dosage level that is in the range of from about .2 mg. to about 0.5 mg. per kg. of body weight per day is most desirably employed in order to achieve effective results.

The following examples are given by way of illustration and are not to be construed as limitations of this invention, many variations of which are possible without departing from the scope and spirit thereof.

EXAMPLE I l-(4-Diethylamino-2-butynyl )-2-Pyrrolidinone Analysis- Ialculated for c,,H. ,N .O: C. 69.19; H,968; N 13.45 l ound: c, 68.90; H, 9 43-, N, 13.43

EXAMPLE ll l(4-Piperidino-2-butynyl)-2-Pyrrolidinone This compound was prepared by the method del-(4-[4-Methylpiperazino]-2-butynyl)-2-Pyrrolidinone 1 3,856,790 3 4 scribed in Example I, using piperidine in place of dieth- The compound l-propargyl-2-pyrrolidinone is reylamine. The fraction boiling at l26l40/0.l mm. acted with formaldehyde and 4-methylpiperazine in the was collected (12.45 g.). On redistillation, the product manner described for Example I to give the title comboiled at l36l38/0.l mm. Analysis: Calculated for pound. C H N O: C, 70,87; H, 9.15: N, 12.72 Found: C,

70.92; H, 9.03; N, 12.50 EXAMPLE V1 Following the procedure described in Example I. the EXAMPLE compounds listed in the Table below are reacted to l-(4-Morpholino-2-butynyl)-2-Pyrrolidinone give the respective compounds of the invention:

' Table Ex. Propargyl Amine Compound Carbonyl Compound Amine Compound Product Compound Vl l-Propargyl-Z-oxopiperidine Formaldehyde Ethylbenzylamine l-(4-Ethylbenzylamino-2-butynyh- 2-oxopiperidine Vll l-Propargyl-Z-pyrrolidinone Fon'naldehyde 2,5-Pyrrolidindione l-[4-(2,5-Pyrrolidindione-2- butynyl )]-2 -pyrrol|dinone VIII 1 -Propargyl-2-pyrrolidinone Formaldehyde 2-Thio-pyrrolidone 1-[4-( 2-Tlnopyrroli done-2- butynglH-Z-pyrrohdmone IX l -Propargyl-2-pyrrolidinone Formaldehyde Dibutylamine l-(4- rdbutylammo-2-butynyl )-2- v pyrrormone X l -Propargyl-2-pynolidinone Formaldehyde Dibenzylamine l-(4-l3atgenzylanuno-2-butynyl )-2- pyrro i rnone Xl l-Propargyl-2-oxopiperidine Benzaldehyde Dibutylamine l-(4-D1butylammo- 1 henyl-2- butynylQ-Z-oxo lpen me Xll l-Propargyl-Z-pyrrolidinone Butyraldehyde Dimethylamine 1-[(4-Dlmethy ammo)-A-2- heptynyl1-2-pyrrolidinone l-Propargyl-2-pyrrolidinone was reacted with for- We claim: maldehyde and morpholine under the conditions util. A compound of the group having the formula: lized in Examples 1 and ll. The product (13.5 g.) was obtained by distilling through a Vigreaux Column. It boiled at I48 /0.l5 mm. R1

CHz-CE C-CI'IIN Analysis: Rs

Calculated for CWHEMOJ: g, 'Fll, a

Dun wherein R and R when separate, are each of the group consisting of lower alkyl consisting of from 1 to EXAMPLE IV 4 carbon atoms and, when joined, complete a ring of 1. (MOrphoHnO A 2 pemyny|) 2 Pyrm|idimne the group consisting of pipertdino and morpholino.

0 2. A compound as defined in claim 1, which is:

l-(4-diethylamino-2-butynyl) 2-pyrrolidinone. 3. A compound as defined in claim 1, which is: l-(4-piperidino-2-butynyll-2-pyrrolidinone. EXAMPLE V 4. A compound as defined in claim 1, which is:

5 l-(4-morpholino-2-butynyl)-2-pyrrolidinone.

By the reaction of l-propargyl-2-pyrrolidinone with 4 acetaldehyde and morpholine under theconditions of Example I, the title compound is obtained. 

1. A COMPOUND OF THE GROUP HAVING THE FORMULA:
 2. A compound as defined in claim 1, which is: 1-(4-diethylamino-2-butynyl)-2-pyrrolidinone.
 3. A compound as defined in claim 1, which is: 1-(4-piperidino-2-butynyl)-2-pyrrolidinone.
 4. A compound as defined in claim 1, which is: 1-(4-morpholino-2-butynyl)-2-pyrrolidinone. 